These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8938914)

  • 1. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.
    Stanley JA; Williamson PC; Drost DJ; Rylett RJ; Carr TJ; Malla A; Thompson RT
    Schizophr Bull; 1996; 22(4):597-609. PubMed ID: 8938914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Spitzberg K; Kersting A; Arolt V; Heindel W; Pfleiderer B
    Schizophr Res; 2005 Mar; 73(2-3):153-7. PubMed ID: 15653258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
    Théberge J; Al-Semaan Y; Williamson PC; Menon RS; Neufeld RW; Rajakumar N; Schaefer B; Densmore M; Drost DJ
    Am J Psychiatry; 2003 Dec; 160(12):2231-3. PubMed ID: 14638596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study.
    Sigmundsson T; Maier M; Toone BK; Williams SC; Simmons A; Greenwood K; Ron MA
    Schizophr Res; 2003 Nov; 64(1):63-71. PubMed ID: 14511802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
    Natsubori T; Inoue H; Abe O; Takano Y; Iwashiro N; Aoki Y; Koike S; Yahata N; Katsura M; Gonoi W; Sasaki H; Takao H; Kasai K; Yamasue H
    Schizophr Bull; 2014 Sep; 40(5):1128-39. PubMed ID: 24023251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia.
    Aoyama N; Théberge J; Drost DJ; Manchanda R; Northcott S; Neufeld RW; Menon RS; Rajakumar N; Pavlosky WF; Densmore M; Schaefer B; Williamson PC
    Br J Psychiatry; 2011 Jun; 198(6):448-56. PubMed ID: 21628707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia.
    Yamasue H; Fukui T; Fukuda R; Kasai K; Iwanami A; Kato N; Kato T
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):353-60. PubMed ID: 14604450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia.
    Deicken RF; Zhou L; Schuff N; Weiner MW
    Schizophr Res; 1997 Oct; 27(1):65-71. PubMed ID: 9373896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.
    Kegeles LS; Mao X; Stanford AD; Girgis R; Ojeil N; Xu X; Gil R; Slifstein M; Abi-Dargham A; Lisanby SH; Shungu DC
    Arch Gen Psychiatry; 2012 May; 69(5):449-59. PubMed ID: 22213769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.
    van Elst LT; Valerius G; Büchert M; Thiel T; Rüsch N; Bubl E; Hennig J; Ebert D; Olbrich HM
    Biol Psychiatry; 2005 Nov; 58(9):724-30. PubMed ID: 16018980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study.
    Gan JL; Cheng ZX; Duan HF; Yang JM; Zhu XQ; Gao CY
    Psychiatry Res; 2014 Jul; 223(1):23-7. PubMed ID: 24831926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.
    Théberge J; Bartha R; Drost DJ; Menon RS; Malla A; Takhar J; Neufeld RW; Rogers J; Pavlosky W; Schaefer B; Densmore M; Al-Semaan Y; Williamson PC
    Am J Psychiatry; 2002 Nov; 159(11):1944-6. PubMed ID: 12411236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.
    Bartha R; Williamson PC; Drost DJ; Malla A; Carr TJ; Cortese L; Canaran G; Rylett RJ; Neufeld RW
    Arch Gen Psychiatry; 1997 Oct; 54(10):959-65. PubMed ID: 9337777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.
    Abbott C; Bustillo J
    Curr Opin Psychiatry; 2006 Mar; 19(2):135-9. PubMed ID: 16612192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.
    Snitz BE; MacDonald A; Cohen JD; Cho RY; Becker T; Carter CS
    Am J Psychiatry; 2005 Dec; 162(12):2322-9. PubMed ID: 16330597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.
    Iwata Y; Nakajima S; Plitman E; Caravaggio F; Kim J; Shah P; Mar W; Chavez S; De Luca V; Mimura M; Remington G; Gerretsen P; Graff-Guerrero A
    Biol Psychiatry; 2019 Apr; 85(7):596-605. PubMed ID: 30389132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla.
    Théberge J; Al-Semaan Y; Drost DJ; Malla AK; Neufeld RW; Bartha R; Manchanda R; Menon R; Densmore M; Schaefer B; Williamson PC
    Psychiatry Res; 2004 Jul; 131(2):107-14. PubMed ID: 15313517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus.
    Yoo SY; Yeon S; Choi CH; Kang DH; Lee JM; Shin NY; Jung WH; Choi JS; Jang DP; Kwon JS
    Schizophr Res; 2009 Jun; 111(1-3):86-93. PubMed ID: 19406622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.